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Albino Oxford (AO) rats are extremely resistant to induction of experimental autoimmune 
encephalomyelitis (EAE). EAE is an animal model of multiple sclerosis, a chronic inflam-
matory disease of the central nervous system (CNS), with established autoimmune 
pathogenesis. The autoimmune response against the antigens of the CNS is initiated 
in the peripheral lymphoid tissues after immunization of AO rats with CNS antigens. 
Subsequently, limited infiltration of the CNS occurs, yet without clinical sequels. It has 
recently become increasingly appreciated that gut-associated lymphoid tissues (GALT) 
and gut microbiota play an important role in regulation and propagation of encephalito-
genic immune response. Therefore, modulation of AO gut microbiota by antibiotics was 
performed in this study. The treatment altered composition of gut microbiota in AO rats 
and led to a reduction in the proportion of regulatory T cells in Peyer’s patches, mesen-
teric lymph nodes, and in lymph nodes draining the site of immunization. Upregulation 
of interferon-γ and interleukin (IL)-17 production was observed in the draining lymph 
nodes. The treatment led to clinically manifested EAE in AO rats with more numerous 
infiltrates and higher production of IL-17 observed in the CNS. Importantly, transfer of 
AO gut microbiota into EAE-prone Dark Agouti rats ameliorated the disease. These 
results clearly imply that gut microbiota is an important factor in AO rat resistance to EAE 
and that gut microbiota transfer is an efficacious way to treat CNS autoimmunity. These 
findings also support the idea that gut microbiota modulation has a potential as a future 
treatment of multiple sclerosis.
Keywords: experimental autoimmune encephalomyelitis, multiple sclerosis, gut microbiota, gut-associated 
lymphoid tissue, antibiotics, gut microbiota transfer
Abbreviations: AO, Albino Oxford; Antb, antibiotics; c.s., clinical score; CFA, complete Freund’s adjuvant; CNS, central nerv-
ous system; Ctrl, control; d.p.i., days post immunization; DA, Dark Agouti; DGGE, denaturing gradient gel electrophoresis; 
EAE, experimental autoimmune encephalomyelitis; FCS, fetal calf serum; GALT, gut-associated lymphoid tissue; Gmbt, gut 
microbiota transfer; IFN, interferon; IL, interleukin; MBP, myelin basic protein; MLN, mesenteric lymph node; MLNC, MLN 
cells; OTU, operational taxonomic units; PBS, phosphate buffer saline; PCR, polymerase chain reaction; PP, Peyer’s patch; PPC, 
PP cells; Th, helper T cells; Treg, regulatory T cells.
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inTrODUcTiOn
The origin of adaptive immune system has been associated with 
establishment of a commensal relation of vertebrates and gut 
microorganisms (1). Also, it is becoming increasingly appreci-
ated that the immune system is deeply influenced by the gut 
microorganisms (2). Therefore, it does not come as a surprise 
that autoimmunity, as one of the major disorders arising from 
inappropriate activity of the adaptive immune system, has been 
tightly connected to gut microbiota perturbations (3). Multiple 
sclerosis is a chronic inflammatory disease of the central nervous 
system (CNS). While autoimmune response directed against the 
CNS has been considered as the major element of the disease 
pathogenesis, the initial steps of the autoimmunity have still 
remained elusive (4). Based on data obtained from studies on 
animal models of multiple sclerosis the role of gut microbiota in 
the initiation of the CNS autoimmunity has been suggested (4). 
The primary step in the autoimmune process is activation of the 
CNS-reactive autoimmune CD4+ T cells (T helper, Th cells) that 
differentiate toward interferon (IFN)-γ-producing Th1 cells and 
interleukin (IL)-17-producing Th17 cells (5). Molecular mimicry 
between gut microbes and the CNS antigens has been suggested 
as a possible scenario for activation and differentiation of the CNS 
autoreactive Th1 and Th17 cells within the GALT (4, 6). Although 
direct evidences on the role of gut microbiota in the autoimmune 
pathogenesis of multiple sclerosis are still missing, there are cor-
relative studies that show that intestinal microbiota is changed, 
presumably dysbiotic in multiple sclerosis patients. For instance, 
lower abundance of Faecalibacterium (7), clostridia clusters 
XIVa, IV, Bacteroides fragilis, Sutterella wadsworthensis (8), 
Butyricimonas (9), Parabacteroides, Adlercreutzia, and Prevotella 
operational taxonomic units (10) was detected in multiple scle-
rosis patients. In contrast, Methanobrevibacter and Akkermansia 
(9), Pseudomonas, Mycoplana, Haemophilus, Blautia, and Dorea 
genera (10) were increased in the patients. Recently published 
reports reveal new bacterial genera over presented in multiple 
sclerosis microbiome such as Acinetobacter (11). Moreover, evi-
dence for the functional significance of altered multiple sclerosis 
microbiota was provided by its transfer into germ free mice which 
resulted in potentiating experimental autoimmune encephalo-
myelitis (EAE) clinical signs (11). Alike, higher incidence of CNS 
autoimmunity in spontaneous model of EAE after colonization 
of germ-free RR mice with microbiota from multiple sclerosis 
affected twins compared to that obtained from healthy twins (12). 
Discovery of multiple sclerosis-related pathogenic and/or protec-
tive gut microbiota organisms or their products would open novel 
opportunities for diagnosis and therapy of the disease. The latter 
would rely on antibiotic (Antb) and/or probiotic treatments, as 
well as on gut microbiota transfer from healthy donors. However, 
it is already known that gut microbiota is individually tailored and 
that it is hard to efficiently change composition of gut microbiota 
(13). Thus, further studies with experimental models are needed.
Our primary aim was to explore whether perturbation of 
gut microbiota reflects on susceptibility to induction of EAE, 
an animal model of multiple sclerosis. Albino Oxford (AO) rats 
resistant to induction of EAE and Dark Agouti (DA) rats prone 
to the disease (14) were used in this study. We have recently 
shown that these two rat strains differ in composition of their gut 
microbiota (15, 16). Higher diversity of bacteria was detected in 
DA rats. Specifically, in most of AO rat samples only lactobacilli 
and enterococci were detected, while DA rat samples contained 
other bacteria, including Lachnospiraceae, Firmicutes, and 
Proteobacteria (Burkholderiales, Undibacterium oligocarbon-
iphilum) (15, 16). Moreover, AO gut microbiota did not change 
considerably after EAE immunization, while extensive changes 
were demonstrated in DA rats after the immunization. Therefore, 
it was plausible to assume that AO gut microbiota contributed to 
their resistance to EAE induction. Antb treatment was used in 
our experiments to disturb AO gut microbiota and to overcome 
their resistance to EAE induction. Further, our goal was to test 
if gut microbiota transfer from AO rats to EAE-prone DA rats 
would change DA gut microbiota composition and consequently 
protect them from the disease. Cecal content was grafted in our 
experiments as it was a reliable source of gut microorganisms.
MaTerials anD MeThODs
experimental animals and eae
Female AO and DA rats were bred and maintained in the 
animal facility of the Institute for Biological Research “SiniŠa 
StankoviĆ.” Animal experiments were approved by the local 
ethics committee (Institute for Biological Research “SiniŠa 
StankoviĆ,” No. 04-04/15). Housing of the rats was performed 
under the same environmental conditions. Three to five rats 
were kept in the same cage. EAE was induced with DA rat spinal 
cord homogenate (SCH) in phosphate buffer saline (PBS, 50% 
w/v) mixed with equal volume of complete Freund’s adjuvant 
(CFA, Difco, Detroit, MI, USA) supplemented with 5 mg/ml of 
M. tuberculosis H37Ra (Difco). Alternatively, rats were immu-
nized with myelin basic protein (guinea pig MBP, 50 μg/rat, 
kind gift from Professor Alexander Flügel, University of 
Göttingen, Germany), emulsified with equal volume of CFA sup-
plemented with 5 mg/ml of M. tuberculosis H37Ra. MBP + CFA 
immunization was performed for subsequent antigen-specific 
production of cytokines that was determined in cells of lymph 
nodes draining the site of injection [popliteal lymph nodes 
(PLN) were extracted from the rats on day 4 and day 7 after the 
immunization]. The animals were injected subcutaneously into 
hind limbs with 100 µl of either emulsion. The rats were moni-
tored daily for clinical score (c.s.) of EAE, and scored according 
to the following scale: 0, no clinical signs; 1, flaccid tail; 2, hind 
limb paresis; 3, hind limb paralysis; 4, moribund state or death. 
Cumulative c.s. was calculated as sum of daily c.s. Duration was 
number of days that the clinical signs were observed in each of 
the rats. Mean c.s. was calculated as cumulative c.s. divided by 
duration. In order to detect inflammatory infiltrates in the CNS 
of immunized animals, hematoxylin and eosin staining was 
performed. The stained cells were counted from five animals. 
Five micrometers of transversal lumbosacral sections (L1–L5) 
were cut and eight successive slices were placed on the same 
glass slide. Number of infiltrates and cells per infiltrate were 
counted from histological data obtained from 120 sections 
per group.
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antb Treatment
Antibiotic treatment consisted of 2.5  g/l of neosulfox 
[Sulfadimidine sodium 10% (w/w), neomycin sulfate 6%, oxytet-
racycline hydrochloride4%, “Fm Pharm” d.o.o., Subotica], 2.5 g/l 
pentrexyl (ampicillin, Galenika, Belgrade, Serbia). The Antb were 
applied to AO rats in drinking water and changed regularly every 
second day. The treatment started at the day of birth and was 
introduced to rats gradually from 0.5 to 2.5 g/l. The full dosage 
was achieved at day 7 postpartum. Rats were allowed to drink the 
water with Antb ad libitum for 4 weeks, i.e., throughout the dura-
tion of the preweaning period. Then, rats were separated from 
mothers and were left without additional treatment till week 8 
when they were immunized. Control (Ctrl) rats were maintained 
in parallel. The treated and Ctrl rats were offspring of littermate 
male and littermate female rats.
gut Microbiota Transfer
For gut microbiota transfer (fecal transplantation), cecal content 
obtained from adult healthy untreated AO rats (2–4 months old) 
was dissolved in physiological saline (one cecum per 40 ml) and 
filtered through filter paper. This was further diluted with drink-
ing water and applied to DA rats ad libitum. Ctrl DA rats had the 
same amount of physiological saline in their drinking water. Also, 
feces obtained from AO rat beddings was transferred into clean 
DA rat beddings. The combined treatment started 1 week before 
birth of pups and lasted for 12 weeks. Ctrl rats did not receive 
feces from AO rat beddings. The rats were immunized at age of 
8  weeks. The treated and Ctrl rats were offspring of littermate 
male and littermate female rats.
Denaturing gradient gel electrophoresis 
(Dgge) analysis and Dna sequencing
Feces was collected from rats on separation (4 weeks of age), on 
the day of immunization (8 weeks of age) and after the immuni-
zation (9 and 10 weeks of age) and stored at −20°C. Extraction 
of bacterial DNA from frozen fecal samples was done using the 
QIAamp DNA stool minikit (Qiagen, Hilden, Germany). DGGE 
analysis and gel manipulation after electrophoresis was entirely 
performed as described previously (17). The primer set Lab-
0159f and Uni-0515-GCr (Metabion International, Martinsried, 
Germany), complementary to lactobacilli and related lactic acid 
bacteria (LAB), as well as the universal primer set U-968-GC-f 
pared with L1401-r, complementary to 16S rDNA specific for 
Eubacteria were used (18, 19). Fragments of interest were excised 
from the gel and macerated, and the suspension was incubated 
for 10  min at 98°C (17). After incubation, the suspension was 
centrifuged to pellet gel particles. The supernatant (30  µl) was 
used in polymerase chain reaction (PCR) with Lab-0159f and 
Uni-0515GCr primers (18). The obtained PCR products were 
purified using the QIAquick PCR purification kit (Qiagen) and 
ligated into the pJET1.2/blunt vector (CloneJET PCR Cloning 
Kit, Thermo Scientific). Ligated constructs were transformed in 
Ca2-induced competent DH5α cells (20), and insert-containing 
transformants were selected as white colonies on Luria-Bertani 
agar plates containing 100 µg/ml ampicillin and 20 µg/ml X-Gal 
(5-bromo-4-chloro-3-indolyl-β-d-galactoside) as recommended 
by Promega. For each excised DNA band, one white colony 
was picked and plasmids were isolated using the QIAprep spin 
miniprep kit (Qiagen). The sequencing of the isolated insert-
containing pJET1.2/blunt plasmids was done with pJET1.2 
sequencing primers at Macrogen Europe Service, Amsterdam, 
Netherlands. Sequence annotation and the database searches 
for sequence similarities were performed with the BLAST tool 
available online.
isolation of cells, cell culturing,  
and generation of supernatants
Cells of lymph nodes draining the site of immunization (PLN) 
were obtained from rats immunized with 100  µl of emulsion 
made of MBP and CFA, as described above. PLN cells (PLNC) 
were obtained by mechanical disruption. The isolation took place 
at 4, 7, and 14 days post immunization (d.p.i.). Mesenteric lymph 
nodes (MLNs) and Peyer’s patches (PP) were isolated from non-
immunized rats and from rats on 4, 7, and 14 d.p.i. Four MLN 
were isolated from each rat and MLN cells (MLNC) were pre-
pared by mechanical disruption. PP were obtained from the small 
intestine and PP cells (PPC) were obtained by mechanical disrup-
tion. PLNC were cultured in RPMI 1640 culture medium (PAA 
Laboratories, Pasching, Austria) that was supplemented with 2% 
rat serum. The cells were seeded at 5 ×  106/ml/well in 24-well 
plates (Sarstedt, Nümbrecht, Germany) and stimulated with MBP 
(10 µg/ml). MLNC and PPC were grown in RPMI1640 medium 
supplemented with 5% fetal calf serum (PAA Laboratories). 
MLNC (2.5 ×  106/ml) and PPC (2 ×  106/ml) were stimulated 
with concanavalin A (ConA, Sigma-Aldrich, 2.5 µg/ml). Cultures 
lasted for 24 h and subsequently cell culture supernatants were 
collected and kept frozen until assayed. Supernatants were also 
obtained from SCHs (1 g of spinal cord homogenized in 2 ml of 
PBS) after centrifugation on 10,000 g for 20 min.
cytofluorimetry
Cells were stained with the following antibodies: PE-conjugated 
anti-CD4 (mouse monoclonal OX35, eBioscience) and FITC-
conjugated anti-CD25 (mouse monoclonal NDS601, AbD 
Serotec, Oxford, UK). PE/Cy5-conjugated FoxP3 staining with 
rat monoclonal antibody (FJK-16s) was performed according 
to the procedure suggested by the manufacturer (eBioscience). 
Appropriate isotype Ctrl antibodies were used where necessary 
to set gates for cell marker positivity. Typically, proportion of 
isotype Ctrl antibody-stained cells was <1%. Cells were gated to 
live cells (gate R1 based on FSC/SSC). Proportion of FoxP3+ cells 
was determined among CD4+CD25+ cells (gate Q2). Analyses 
were performed on a Partec CyFlow Space cytometer (Partec, 
Munster, Germany). Results of cytofluorimetry are presented as 
proportion of cells bound by an appropriate antibody.
elisa
Cytokine concentration in supernatants was determined by sand-
wich ELISA using MaxiSorp plates (Nunc, Rochild, Denmark). 
For IL-10 detection Rat IL-10 DuoSet ELISA was used according 
to the manufacturer’s instructions (R&D Systems, Minneapolis, 
MN, USA). For IFN-γ and IL-17 detection anti-cytokine paired 
Table 1 | Bacteria sequences.
no. of 
band
species determined by sequencing of  
16s rDna
identity 
(%)
1 Lactobacillus murinus strain NBRC 14221  
16S ribosomal RNA gene, partial sequence
99
2 L. murinus strain NBRC 14221 16S ribosomal  
RNA gene, partial sequence
100
3 L. murinus strain NBRC 14221 16S ribosomal  
RNA gene, partial sequence
99
4 Lactobacillus intestinalis strain TH4 16S ribosomal  
RNA gene, partial sequence
98
5 L. intestinalis strain TH4 16S ribosomal RNA gene,  
partial sequence
99
6 L. intestinalis strain TH4 16S ribosomal RNA gene,  
partial sequence
99
7 Lactobacillus gasseri strain ATCC 33323 16S  
ribosomal RNA gene, complete sequence
99
8 L. gasseri strain ATCC 33323 16S ribosomal  
RNA gene, complete sequence
99
9 Roseburia intestinalis strain DSM 14610 16S  
ribosomal RNA gene, partial sequence/Roseburia  
inulinivorans strain A2-194 16S ribosomal RNA gene,  
complete sequence/Roseburia hominis strain A2-183  
16S ribosomal RNA gene, complete sequence/Roseburia  
faecis strain M72/1 16S ribosomal RNA gene,  
partial sequence (84%) Roseburia sp.
84
10 L. intestinalis strain TH4 16S ribosomal RNA gene,  
partial sequence
99
11 Lactobacillus faecis strain AFL13-2 16S ribosomal  
RNA gene, partial sequence
99
4
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antibodies were used according to the manufacturer’s instruc-
tions (eBioscience, San Diego, CA, USA). The antibodies were as 
follows: anti-rat IFN-γ purified mouse monoclonal (DB1), anti-
rat IFN-γ biotinylated rabbit polyclonal, anti-mouse/rat IL-17A 
purified rat monoclonal (eBio17CK15A5), and anti-mouse/rat 
IL-17A biotinylated rat monoclonal (eBio17B7). Samples were 
analyzed in duplicates and the results were calculated using 
standard curves made on the basis of known concentrations of 
the recombinant rat IL-10 (R&D Systems) and IFN-γ and IL-17 
(Peprotech, Rocky Hill, NJ, USA).
statistical analysis
Two-way ANOVA followed with Student’s t-test (two-tailed) or 
Mann–Whitney U test, as appropriate was performed for statisti-
cal analysis. A p-value less than 0.05 was considered statistically 
significant. Differences in DGGE profiles of gut microbiota in 
various animal groups were calculated by Dice similarity coef-
ficient. Similarity between single groups was determined as:
 Dsc = × / +2 100 ,j a b  
where, a is the number of DGGE bands in one group; b is the 
number of DGGE bands in second group; j is the number of the 
same bands in both groups. Dsc =  100 represents completely 
identical DGGE profiles, while Dsc =  0 represents completely 
different DGGE profiles.
resUlTs
antb Treatment changes gut Microbiota 
composition in aO rats
Albino Oxford rats were treated with Antb to perturb their gut 
microbiota. The treatment started at the day of birth and lasted 
for 4 weeks. Thus, pups were exposed to Antb indirectly through 
dams. Fecal samples were collected at the point of weaning which 
corresponded to cessation of Antb treatment (4  weeks of age), 
as well as at the time of immunization (0 d.p.i., 8 weeks of age). 
Fecal samples were also collected after SCH + CFA immunization 
in the inductive phase of EAE (7 days p.i., 9 weeks of age) and at 
the time of clinically manifested disease (14 days p.i. 10 weeks 
of age). DGGE analysis of rDNA amplicons using DNA isolated 
from fecal samples as templates and Lab-0159f and Uni-0515GCr 
primer set was performed. The treatment led to the change 
in DGGE profile of gut microbiota at week 4, where specific 
DGGE bands representing core microbiota in Ctrl samples 
(e.g., Lactobacillus murinus and Lactobacillus intestinalis, Table 1) 
were absent in samples from Antb-treated rats (Figure  1). 
However, the changes were less prominent at weeks 8, 9, and 10, 
due to relative heterogeneity of the samples (Figure 1). Thus, Antb 
treatment led to transient change in gut microbiota composition 
in AO rats. Specific differences that were determined by sequenc-
ing are presented at Figure 1, while annotated bacterial species 
are given in Table 1. Presence of L. murinus in Antb-treated rats 
and of L. intestinalis in Ctrl rats at 0 d.p.i. suggests that L. murinus 
colonizes in opportunistic way, when competition is reduced. Still 
the differences in the presence of L. intestinalis are lost at 14 d.p.i. 
Interestingly, Roseburia sp., butyrate producing commensal 
bacteria and Lactobacillus gasseri were observed exclusively in 
Antb-treated rats at 7 and 14 d.p.i.
antb Treatment affects Plnc
Cellularity, phenotypic analysis, and MBP-stimulated cytokine 
production of PLN was compared in Antb-treated and Ctrl AO rats 
at different time points after the immunization. Number of cells per 
PLN was significantly higher in Antb-treated rats at 4 d.p.i., but not 
at 7 and 14 d.p.i. (Figure 2A). Percentage of CD4+CD25+Foxp3+ 
regulatory T cells (Treg) was reduced in Antb-treated rats at 4 d.p.i. 
(Figures 2B,C,G,H). At the same time, higher levels of IFN-γ and 
IL-17, but not of IL-10 were observed in MBP-stimulated PLNC 
obtained from Antb-treated rats (Figures 2D–F).
antb Treatment affects Mlnc and PPc
Cellularity, phenotypic analysis, and ConA-stimulated cytokine 
production of MLN and PP were determined in Antb-treated and 
Ctrl non-immunized AO rats, as well as at different time points 
after the immunization. Number of cells and proportion of CD4+ 
cells in MLN and PP was without difference in Ctrl and Antb-
treated rats in all examined time points (Figures  3A,B,D,E). 
Percentage of Treg was lower in MLN of Antb-treated rats on 4 
and 7 d.p.i., and in PP before the immunization, at day 4 d.p.i. and 
at 14 d.p.i. (Figures 3C,F,J,K). Production of IFN-γ, IL-17, and 
FigUre 1 | Effects of antibiotic (Antb) treatment on Albino Oxford (AO) rat gut microbiota composition. AO rats, untreated [control (Ctrl)] or treated with Antb, were 
immunized with spinal cord homogenate + complete Freund’s adjuvant and samples were collected as depicted (a). Denaturing gradient gel electrophoresis (DGGE) 
profiles of rDNA amplicons obtained using a Lactobacillus-specific primer set on bacterial DNA isolated from fecal samples of AO rats (b). Each lane represents 
sample of an individual rat. Arrows represent DGGE bands present in Ctrl samples and absent in samples from Antb-treated rats at 4 weeks of age. The annotated 
species of the sequenced DGGE bands (1–11) are given in Table 1.
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IL-10 was without difference in MLN of Ctrl and Antb-treated 
rats before the immunization and on 7 d.p.i., yet production of 
IFN-γ, but not the other two cytokines was significantly higher 
in Antb-treated rats on 4 d.p.i. (Figures 3G–I).
antb Treatment induces eae in aO rats
In order to test if the observed changes in gut microbiota, PLN, 
MLN, and PP have any relevance for pathogenesis of EAE the 
groups of Antb-treated and untreated rats, both immunized 
with SCH-CFA were followed for 40  days in order to evaluate 
clinical and histological manifestations of disease. Unlike Ctrl 
untreated rats that were uniformly without any clinical signs 
during the observation period, more than 50% of Antb-treated 
rats expressed mild clinical signs of EAE (Table 2; Figure 4A). 
The broken resistance to EAE was paralleled with more numerous 
spinal cord infiltrates and higher number of cells per infiltrate 
(Figures  4B,C). Also, level of IL-17 was significantly higher 
in supernatants of SCHs obtained from Antb-treated AO rats 
(Figure 4D). Interestingly, IFN-γ level was significantly reduced 
in these supernatants (Figure 4D).
aO rat gut Microbiota Transfer 
ameliorates eae in Da rats
Finally, to investigate potential beneficial effects of AO gut micro-
biota, its transfer into EAE-prone DA rats was performed. DA 
rats were continuously exposed to AO gut microbiota from birth. 
EAE was induced when rats were 8 weeks of age (Figure 5A). The 
disease was ameliorated in AO gut microbiota-transferred DA rats 
in comparison to untreated counterparts (Figure 5B; Table 3). 
IL-17, but not IFN-γ level was decreased in SCHs of the treated rats 
(Figure 5C). The treatment led to decrease in number of PLNC 
in the inductive phase of the disease (4 and 7 d.p.i.) (Figure 5D). 
FigUre 2 | Effects of antibiotic (Antb) treatment on PLN cells (PLNC). Albino Oxford rats were untreated [control (Ctrl)] or treated with Antb and they were 
immunized with spinal cord homogenate + complete Freund’s adjuvant (CFA) (a–c,g,h) or with myelin basic protein + CFA (D–F). PLNC were isolated from  
rats at 4, 7, and 14 days post immunization (d.p.i.). Cellularity (a), CD4 proportion (b), regulatory T cell (Treg) proportion (c), interferon (IFN)-γ levels (D), IL-17  
levels (e), and IL-10 levels (F) were determined. The total number of samples obtained in at least three independent experiments was 20 (a), 24 (b,c), and 9  
(D–F) per group. Data are presented as mean ± SD. Representative plots obtained at 4 d.p.i. are showing gating strategy for Treg (g,h). *p < 0.05 Antb vs.  
Ctrl (t-test).
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There was no difference in cellularity of MLN (Figure 5G), nor 
in proportion of CD4+ T cells in lymph nodes (Figures 5E,H). 
Importantly, proportion of Treg was increased both in draining 
and MLNs at the same time (Figures 5F,I,J,K).
In order to determine the influence of AO gut microbiota 
transfer on DA gut microbiota, DGGE analysis of rDNA ampli-
cons obtained by using DNA isolated from fecal samples of AO 
(Donor) and DA (gut microbiota-transferred—Gmbt and Ctrl) 
rats as templates and Lactobacillus sp.-specific primers comple-
mentary to 16S of lactobacilli and related LAB (Figures 6A–C) 
and universal primers complementary to 16S rDNA regions 
of Eubacteria (Figures  6D–F). The presence of specific clearly 
visible bands in DGGE profiles was analyzed by Dice similarity 
coefficient. The results of the analysis revealed that the trans-
fer of AO gut microbiota to DA rats significantly (p <  0.05) 
influenced the diversity of gut microbiota in the treated DA 
rats (Figures  6C,F). Particularly, LAB diversity of the DA rats 
after gut microbiota transfer (Gmbt) was significantly (p < 0.05) 
different comparing to Ctrl animals in the period from weaning 
to the day of immunization. At the same time, Dice coefficient 
was significantly higher for AO and Gmbt group (nearly 100%), 
which points to the successful transplantation of LAB strains 
from AO to Gmbt group. Four weeks after the weaning the 
similarity in LAB strains composition between AO and Gmbt 
groups starts to decrease, but at the same time the coefficient 
starts to increase between Ctrl and Gmbt groups pointing to the 
returning of LAB composition to the composition in the Ctrl 
group. Additionally, the similarity of LAB composition between 
these two groups starts to decrease again at 14  d.p.i., which 
is probably the effect of immune mechanisms on microbiota 
FigUre 3 | Effects of antibiotic (Antb) treatment on MLN cells (MLNC) and PP cells (PPC). Albino Oxford rats were untreated [control (Ctrl)] or treated with Antb. 
MLNC (a–c,g–i,J) and PPC (D–F,K) were isolated from rats at 0, 4, 7, and 14 days post immunization (d.p.i.) (spinal cord homogenate + complete Freund’s 
adjuvant). Cellularity (a,D), phenotype (b,c,e,F), and cytokine generation (g–i) were determined. The total number of samples obtained in at least three 
independent experiments was 12 (a,c), 24 (b,c,D,e), 7 (g–i) per group. Data are presented as mean ± SD. Representative plots obtained at 4 d.p.i. are  
showing gating strategy for regulatory T cells (Treg) in MLNC (J) and PPC (K).*p < 0.05 Antb vs. Ctrl (t-test).
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Table 2 | Effects of antibiotic (Antb) treatment on Experimental Autoimmune 
Encephalomyelitis.
incidence Duration 
(days)
Mean  
c.s.
cumulative 
c.s.
Maximal 
c.s.
Control 0/20 0 0 0 0
Antb 9/17 3.0 ± 1.9 0.6 ± 0.1 1.8 ± 1.3 0.7 ± 0.3
Results are presented as mean ± SD.
c.s., clinical score.
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composition (Figure  6C). Similarly, the total gut microbiota 
diversity of Gmbt DA rats was significantly (p < 0.05) different 
comparing to Ctrl animals (Ctrl) in the period from 0 to 7 d.p.i., 
while the similarity between AO and Ctrl DA rats is the lowest 
at 7 d.p.i. indicating that this difference could be crucial for the 
disease prognosis (Figure 6F).
DiscUssiOn
The results of this study show that prolonged oral application 
of Antb to AO rats modifies their gut microbiota and GALT. 
Subsequently, this treatment stimulates encephalitogenic immune 
response and overcomes resistance of AO rats to EAE. Although 
we do not exclude other possible reasons (genetic, hormonal) 
for the extreme resistance of AO rats to EAE induction observed 
in our previous studies (14, 21), the observed annulation of the 
resistance through the Antb treatment is a compelling result 
despite mild clinical symptoms that were achieved. Gut microbi-
ota-independent effects of Antb on EAE susceptibility in AO rats 
cannot be disregarded. However, the substantial modification of 
AO gut microbiota determined after the Antb treatment allows 
us to assume that the observed effects of Antb on EAE suscep-
tibility in AO rats are, at least partly, gut microbiota-mediated. 
These effects were associated with reduction of regulatory T cells 
(Treg) and upregulation of pro-inflammatory components in 
lymph organs and within the CNS. Importantly, the effects were 
mostly observed in early inductive phase of the disease (4 d.p.i.), 
i.e., at the time when the autoimmune response was generated. 
This implies that gut microbiota is an important factor of AO 
rat resistance to EAE induction. However, no such distinctive 
differences in gut microbiota have been observed at the time 
when the effect on Treg was detected, indicating that the effect 
on immune system at 4 d.p.i. could be a consequence of Antb-
induced gut microbiota dysbiosis in early-life period (4 weeks of 
age). It is becoming increasingly appreciated that early microbial 
gut colonization highly influences life-long health through the 
interaction with the immune system, while the failure in proper 
immune modulation and induction of immunological tolerance 
could result in development of autoimmune diseases (22).
Gut microbiota and GALT has been proposed as important 
players in initiation, propagation, but also in prevention of 
CNS autoimmunity (4). Indeed, gut microbiota composition is 
different in multiple sclerosis patients and healthy individuals 
(7–10). Accordingly, AO rats that are EAE-resistant have differ-
ent gut microbiota composition in comparison to EAE-prone 
DA rats (15, 16). Also, our previous study showed that cellular 
composition of MLN and PP differ between AO and DA rats, 
the latter having more CD4+ cells and even more Treg (15). 
Here, we present evidence that disturbance of gut microbiota by 
Antb makes AO rats susceptible to EAE induction. There were 
numerous reports on the effect of Antb treatment on EAE that 
did not focus on gut microbiota, but instead used Antb to affect 
other EAE pathogenesis-related components (23–28). Still, there 
were also reports focused on gut microbiota that gave signifi-
cant contribution to our understanding of the role of intestinal 
microbiota in EAE (29, 30). They all presented beneficial effects 
of Antb treatment in EAE. Our results show that Antb can also 
be detrimental in the CNS autoimmunity as AO rats that are 
resistant to EAE develop clinically manifested disease upon Antb 
treatment. These contradictory results could be explained in 
several ways. For instance, the data showing disease-attenuating 
effects of Antb are based on the treatment of adult animals while 
disease-promoting effect demonstrated in our study resulted 
from the Antb application that started in the neonatal period. 
It is well established that environmental factors, nutrients, infec-
tions, and Antb in early-life lead to microbiota alteration with 
considerable consequences on the development and function of 
immune system [reviewed in Ref. (31)]. Indeed, similar results 
were obtained in experimental psoriasis in mice where neonatal 
treatment with Antb increased susceptibility to the disease, while 
the same treatment of adult animals ameliorated this disease (32). 
Also, numerous studies have revealed that different Antb induce 
distinct changes in gut microbiota [reviewed in Ref. (33)], which 
consequently may result in different modulation of the immune 
responses. It has recently been shown that neomycin treatment 
resulted in protection from autoimmune diabetes while vanco-
mycin induced more diabetogenic response in NOD mice (34). 
Thus, the difference in the outcome of Antb treatment, i.e., EAE 
amelioration described by others vs. breakdown of EAE resistance 
which we demonstrate, might be partly ascribed to the use of dif-
ferent combination of Antb. Indeed, it has recently been suggested 
by Qinghui et al. (35), working on gut microbiota modulation in 
a systemic lupus erythematosus animal model, that the appropri-
ate choice of Antb that selectively target harmful bacteria is of 
crucial importance for amelioration of the disease. Importantly, 
the disease was not altered in germ-free mice, thus showing that 
complete absence of gut microbiota did not have any effect on 
the lupus-like disease in mice. In our study, the prolonged Antb 
treatment caused considerable gut microbiota perturbation, 
apparently with absence of major bacterial groups, similar to the 
germ-free status. Particularly, members of the genus Roseburia 
were detected in Antb-treated rats at 14 d.p.i. The perturbations 
of Roseburia spp., previously correlated to immunity maintenance 
and anti-inflammatory properties in gut, was recently correlated 
to various diseases, including irritable bowel syndrome, obesity, 
Type 2 diabetes, nervous system conditions and allergies, while 
the presence of Roseburia spp. showed beneficial effect as pro-
biotic for restoration of beneficial flora (36). Interestingly, the 
gut microbiota diversity was mainly restored during post-Antb 
period, although some specific bacterial groups were altered, in 
comparison to Ctrl groups. Taking into account the appearance 
of the disease symptoms in otherwise EAE-resistant AO rats, it 
could be concluded that the altered microbiota containing higher 
FigUre 4 | Effects of antibiotic (Antb) treatment on experimental autoimmune encephalomyelitis. Albino Oxford rats were untreated [control (Ctrl)] or treated with 
Antb. They were immunized with spinal cord homogenate + complete Freund’s adjuvant and clinical score was determined daily (a). Results are presented as 
mean ± SE of 20 Ctrl and 17 Antb rats in total, from two independent experiments. Spinal cords were isolated at 15 days post immunization and stained with 
hematoxylin. Representative spinal cord sections are presented (b). Number of infiltrates and number of cells per infiltrate is presented as mean ± SD from the total 
number of 120 sections obtained from five rats per group (c). Level of cytokines was determined in spinal cord homogenates. The total number of samples 
obtained in two independent experiments was nine per group (D). Results are presented as mean ± SD. *p < 0.05 Antb vs. Ctrl (t-test).
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Table 3 | Effects of Albino Oxford gut microbiota transfer on experimental autoimmune encephalomyelitis in Dark Agouti rats.
incidence Onset Duration (days) Mean c.s. cumulative c.s. Maximal c.s.
Ctrl 15/15 9.9 ± 1.1 23.6 ± 6.5 0.9 ± 0.2 22.6 ± 9.6 2.4 ± 1.0
Gmbt 13/13 12.2 ± 5.3 18.6 ± 7.6 0.7 ± 0.2* 14.2 ± 8.2* 1.6 ± 0.7*
Results are presented as mean ± SD. c.s., clinical score.
*p < 0.05 Gmbt vs. Ctrl (t-test).
FigUre 5 | Effects of Albino Oxford (AO) gut microbiota transfer on experimental autoimmune encephalomyelitis in Dark Agouti (DA) rats. DA rats were untreated 
[control (Ctrl)] or treated with AO gut microbiota (Gmbt) as represented in scheme (a). They were immunized with spinal cord homogenate + complete Freund’s 
adjuvant and clinical score was determined daily (b). The total number of samples obtained in two independent experiments was 14 per group. Results are 
presented as mean ± SE. Spinal cords were isolated at 14 days post immunization (d.p.i.) and cytokines were measured in supernatants obtained by centrifugation 
of spinal cord homogenates (c). The total number of samples obtained in two independent experiments was four per group. Results are presented as mean ± SD. 
Popliteal lymph node (PLN) (D–F) and mesenteric lymph node (g–i) were isolated at 4 and 7 d.p.i. Cellularity (D,g), percentage of CD4+ T cells (e,h) and regulatory 
T cells (Treg) (F,i) were determined. The total number of samples obtained in two independent experiments was five (D,e,g,h), and nine (F,i) per group. Results  
are presented as mean ± SD. Representative plots obtained at 4 d.p.i. are showing gating strategy for Treg in PLN cells (PLNC) (J) and MLN cells (MLNC)  
(K). *p < 0.05 Gmbt vs. Ctrl [U test (b), t-test (c–i)].
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abundance of harmful bacteria correlated with the promotion of 
autoimmunity and the diseases symptoms.
Autoimmunity-promoting effects of Antb have been demon-
strated before. Besides above mentioned experimental psoriasis 
(32), Antb exacerbated neurological signs and lesions of infection 
induced Guillain–Barré Syndrome in NOD mice (37). Also, Antb 
treatment favored priming of diabetogenic T cells, thus promoting 
disease progression in NOD mice (38) and reestablished expected 
incidence of diabetes in mice previously infected with segmented 
filamentous bacteria to prevent the development of autoimmun-
ity (39). Although simultaneous application of different Antb in 
high doses and for extremely long period is not likely to be used in 
humans, our results call upon caution in Antb use. Importantly, 
our results were obtained from rats treated with Antb from their 
birth till week 4 of their age, i.e., well before the immunization 
(week 8 of their age). This suggests that gut microbiota distur-
bance in the early childhood can predispose an individual toward 
CNS autoimmunity that can be provoked by independent stimuli 
at the latter age. Indeed, differences in rat gut microbiota were 
prominent at the end of the Antb treatment (4 weeks of age), but 
they were almost absent at the time of immunization (8 weeks 
of age). This implied that EAE-promoting effects of Antb were 
achieved through gut microbiota perturbance in the early-life, 
possibly through effect on adaptive immune system development. 
Accordingly, there were less Treg in PP of these rats. Therefore, 
deeper investigation of the effects of early postnatal application of 
Antb on the GALT is needed. Also, our data call upon epidemio-
logical studies that will explore gut microbiota perturbances as a 
consequence of Antb treatment in the early childhood of multiple 
sclerosis patients. Indeed, Antb-induced dysbiosis in children has 
been already proposed as a potential predisposing factor for vari-
ous diseases, including autoimmune ones (40).
It is plausible to assume that the mechanism behind EAE-
promoting effects of Antb observed in AO rats is the functional 
FigUre 6 | Effect of Albino Oxford (AO) gut microbiota transfer to Dark Agouti (DA) rats on microbiota diversity. DA rats were untreated [control (Ctrl)] or treated with 
AO gut microbiota (Gmbt) as represented in Figure 5a. They were immunized with spinal cord homogenate + complete Freund’s adjuvant and fecal samples were 
collected at the time of weaning, at the time of immunization [0 days post immunization (d.p.i.)], as well as at two time points after the immunization (7 and 14 d.p.i.). 
Denaturing gradient gel electrophoresis (DGGE) (a,D). The clearly visible bands were represented as DGGE profiles scheme of rDNA amplicons (b,e) where each 
dot represents a corresponding band on DGGE gel. DGGE gel and profiles obtained using Lactobacillus sp.-specific primers (a,b) and DGGE gel and profiles 
obtained using universal primers (D,e) on bacterial DNA isolated from fecal samples of donor AO rats (Donor), AO gut microbiota-transferred DA rats (Gmbt) and 
Ctrl animals (Ctrl). Each lane represents sample of an individual rat. Box-plot diagram based on Dice similarity coefficient (*p < 0.05) (c,F).
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consequence of changes in microbial composition that deregu-
lated Th1- and Th17-driven immune response. Indeed, draining 
lymph node cells of Antb-treated rats produced more IFN-γ and 
IL-17, marker cytokines of Th1 and Th17, respectively. This prob-
ably came as a consequence of reduced Treg response as lower 
Treg proportion was observed in draining lymph nodes, MLNs, 
and PP after the immunization. This hypothesis is in accordance 
with previous reports on gut microbiota-related effects on EAE. 
For instance, group of Kasper showed in a series of papers that 
beneficial effects of gut microbes on EAE were achieved through 
generation of Tregs that prevented encephalitogenic activity of 
Th cells (41–44). Along the same line, increase in Treg potency 
and subsequent downregulation of Th1/Th17 encephalitogenic 
activity is likely mechanism for the observed beneficial effects of 
AO gut microbiota transfer in DA rats EAE. As a consequence 
of the transfer, increased proportion of Treg was observed in 
draining and MLNs of DA rats after the immunization.
Noteworthy, not only that gut microbiota contributed to the 
resistance of AO rats to the CNS autoimmunity, but its transfer 
into DA rats ameliorated EAE in the recipients. Although the 
similarity in LAB composition between AO and Gmbt DA rats was 
the lowest at 7 d.p.i., when the disease amelioration was observed 
in Gmbt DA rats compared to Ctrl animals, it could be referred 
as the positive impact of AO gut microbiota transfer to DA rats 
during the first days of life. The success of the gut microbiota 
transfer from EAE-resistant rats to EAE-prone rats implies that 
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similar therapeutic approach might be useful in multiple sclerosis. 
Importantly, future studies should determine if EAE-restricting 
effects of gut microbiota are specific for AO rats or similar effects 
could be obtained by transfer of gut microbiota from other rat 
strains, or even with autologous gut microbiota transfer. Also, the 
upcoming studies should investigate if AO gut microbiota has 
beneficial effects in other autoimmune and chronic inflamma-
tory disorders. Gut microbiota transfer seems like a promising 
strategy for the treatment of gut microbiota-related disorders, 
including multiple sclerosis (45). Still, in our experiments DA rats 
were exposed to AO rat gut microbiota from their birth to the 
time of EAE immunization. Such a gut microbiota transfer will 
be feasible in humans only as preventive therapy when genetic 
prediction markers for multiple sclerosis are established. One of 
the main obstacles for successful gut microbiota transfer is the 
resilience of established intestinal microbiota to changes (13). 
While the resilience of “healthy” gut microbiota contributes to 
prevention of dysbiosis-related diseases, the resilience of already 
dysbiotic gut microbiota prevents successful introduction of ben-
eficial microbes in the community. Importantly, it has recently 
been shown that short Antb treatment followed by short gut 
microbiota transfer (both treatments lasting just for two days) 
executed 3 days after EAE immunization protected mice from the 
disease (46). Such a short-lasting efficient treatment of humans 
would be a revolutionary therapeutic advance. Of course, the 
efficiency of the procedure will have to be checked in different 
multiple sclerosis models before translation to humans. Our 
unpublished data show that the same protocol is not efficient in 
transfer of AO rat gut microbiota transfer to DA rats.
Finally, an interesting observation regarding IL-17 and IFN-γ 
production in the spinal cord of Antb-treated AO rats came out, 
as the level of the former was increased and the level of the latter 
was decreased in comparison to untreated EAE Ctrls. Accordingly, 
beneficial effect of AO rat gut microbiota transfer into DA rats 
was paralleled with decrease of IL-17, but increase of IFN-γ in 
the spinal cord. Differential contribution of IL-17- and IFN-
γ-generating cells in the CNS autoimmunity has been already 
acknowledged (47). Different regions of the CNS have been 
preferentially affected by IL-17- or IFN-γ-generating cells and 
as a consequence various clinical outcomes were observed (48). 
Although Th17 cells were dominant in brain and not spinal cord 
inflammation in mice, the opposite was determined in humans 
(48, 49). Our results suggest that rats are more similar to humans 
than mice in that matter. Also, it has been proposed that IFN-γ 
has regulatory property in the brain, but not in the spinal cord of 
mice (48). Still, relatively high IL-17 to IFN-γ ratio in the spinal 
cord seemed to be a hallmark of clinically manifested EAE in AO 
rats, while the opposite ratio was observed with amelioration of 
EAE in DA rats. Further research is needed to investigate if IFN-γ 
has important anti-inflammatory and neuroprotective role in rat 
spinal cords.
To conclude, further studies on multiple sclerosis-related gut 
microorganisms and the ways on successful incorporation of 
beneficial microbes into presumably dysbiotic intestinal micro-
biota community are needed before using gut microbiota transfer 
as a therapy for the disease. Our study contributes to the view that 
gut microbiota is an important factor in the CNS autoimmunity. 
Also, it corroborates the idea that gut microbiota modulation 
could be a useful approach in multiple sclerosis therapy.
eThics sTaTeMenT
This study was carried out in accordance with the recommenda-
tions of the Directive 2010/63/EU of the European Parliament 
and of the Council of 22 September 2010 on the protection of 
animals used for scientific purposes. The protocol was approved 
by the Ethics committee of the Institute for Biological Research 
“SiniŠa Stanković,” No 04-04/15.
aUThOr cOnTribUTiOns
SS: performed main work and analyzed, interpreted, and 
critically revised the data; MD: performed the work related to 
DGGE and sequencing and analysis of the sequenced data; BJ: 
worked on animal model, organ isolation, cell preparation, and 
cytofluorimetry; NĐ: worked on animal model, organ isolation, 
cell preparation, and ELISA; MM: worked on animal model, rat 
treatment, organ isolation, and cell preparation; JĐ: performed 
the DGGE analysis, statistical analysis, and made part of the draft 
related to DGGE analysis; NG: microbiology—conception and 
design, supervised the work, analyzed and interpreted the data, 
and critically revised the manuscript; MS: conception and design 
related to immunology and critically revised the manuscript; 
ĐM: immunology—conception and design, supervised the work, 
analyzed and interpreted the data, drafted the work, and critically 
revised the manuscript. All authors finally approved the version 
to be published and agreed to be accountable for all aspects of 
the work in ensuring that questions related to the accuracy or 
integrity of any part of the work are appropriately investigated 
and resolved.
FUnDing
This work was supported by the Ministry of Education, Science 
and Technological Development of the Republic of Serbia 
(173035, 173019, 175038, and 173013).
reFerences
1. Lee YK, Mazmanian SK. Has the microbiota played a critical role in the 
evolution of the adaptive immune system? Science (2010) 330(6012):1768–73. 
doi:10.1126/science.1195568 
2. Maynard CL, Elson CO, Hatton RD, Weaver CT. Reciprocal interactions of the 
intestinal microbiota and immune system. Nature (2012) 489(7415):231–41. 
doi:10.1038/nature11551 
3. Shamriz O, Mizrahi H, Werbner M, Shoenfeld Y, Avni O, Koren O. Microbiota 
at the crossroads of autoimmunity. Autoimmun Rev (2016) 15(9):859–69. 
doi:10.1016/j.autrev.2016.07.012 
4. Wekerle H. Brain autoimmunity and intestinal microbiota: 100 trillion game 
changers. Trends Immunol (2017) 38(7):483–97. doi:10.1016/j.it.2017.03.008 
5. Petermann F, Korn T. Cytokines and effector T cell subsets causing autoim-
mune CNS disease. FEBS Lett (2011) 585(23):3747–57. doi:10.1016/j.febslet. 
2011.03.064 
13
Stanisavljevic´ et al. Gut Microbiota in EAE Resistance
Frontiers in Immunology | www.frontiersin.org May 2018 | Volume 9 | Article 942
6. Westall FC. Molecular mimicry revisited: gut bacteria and multiple sclerosis. 
J Clin Microbiol (2006) 44(6):2099–104. doi:10.1128/JCM.02532-05 
7. Cantarel BL, Waubant E, Chehoud C, Kuczynski J, De Santis TZ, Warrington J, 
et al. Gut microbiota in multiple sclerosis: possible influence of immunomod-
ulators. J Investig Med (2015) 63:729–34. doi:10.1097/JIM.000000000000019 
8. Miyake S, Kim S, Suda W, Oshima K, Nakamura M, Matsuoka T, et  al. 
Disbiosis in the gut microbiota of patients with multiple sclerosis, with a 
striking depletion of species belonging to clostridia XIVa and IV clusters. 
PLoS One (2015) 10(9):e0137429. doi:10.1371/journal.pone.0137429 
9. Jangi S, Gandhi R, Cox LM, Li N, von Glehn F, Yan R, et al. Alterations of the 
human gut microbiome in multiple sclerosis. Nat Commun (2016) 7:12015. 
doi:10.1038/ncomms12015 
10. Chen J, Chia N, Kalari KR, Yao JZ, Novotna M, Soldan MM, et al. Multiple 
sclerosis patients have a distinct gut microbiota compared to healthy controls. 
Sci Rep (2016) 6:28484. doi:10.1038/srep28484 
11. Cekanaviciute E, Yoo BB, Runia TF, Debelius JW, Singh S, Nelson CA, et al. 
Gut bacteria from multiple sclerosis patients modulate human T  cells and 
exacerbate symptoms in mouse models. Proc Natl Acad Sci U S A (2017) 
114(40):10713–8. doi:10.1073/pnas.1711235114 
12. Berer K, Gerdes LA, Cekanaviciute E, Jia X, Xiao L, Xia Z, et al. Gut micro-
biota from multiple sclerosis patients enables spontaneous autoimmune 
encephalomyelitis in mice. Proc Natl Acad Sci U S A (2017) 114(40):10719–24. 
doi:10.1073/pnas.1711233114 
13. Sommer F, Anderson JM, Bharti R, Raes J, Rosenstiel P. The resilience of the 
intestinal microbiota influences health and disease. Nat Rev Microbiol (2017) 
15(10):630–8. doi:10.1038/nrmicro.2017.58 
14. Momcilović M, Mostarica-Stojković M, Miljković D. CXCL12 in control 
of neuroinflammation. Immunol Res (2012) 52(1–2):53–63. doi:10.1007/
s12026-012-8282-x 
15. Stanisavljević S, Lukić J, Momčilović M, Miljković M, Jevtić B, Kojić M, et al. 
Gut-associated lymphoid tissue, gut microbes and susceptibility to experi-
mental autoimmune encephalomyelitis. Benef Microbes (2016) 7(3):363–73. 
doi:10.3920/BM2015.0159 
16. Stanisavljević S, Lukić J, Soković S, Mihajlovic S, Mostarica Stojković M, 
Miljković D, et al. Correlation of gut microbiota composition with resistance 
to experimental autoimmune encephalomyelitis in rats. Front Microbiol 
(2016) 7:2005. doi:10.3389/fmicb.2016.02005 
17. Lukic J, Strahinic I, Milenkovic M, Golic N, Kojic M, Topisirovic L, et  al. 
Interaction of Lactobacillus fermentum BGHI14 with rat colonic mucosa: 
implications for colitis induction. Appl Environ Microbiol (2013) 79(18): 
5735–44. doi:10.1128/AEM.01807-13 
18. Heilig HGHJ, Zoetendal EG, Vaughan EE, Marteau P, Akkermans ADL, 
de Vos WDL. Molecular diversity of Lactobacillus spp. and other lactic acid 
bacteria in the human intestine by specific amplification of 16S ribosomal DNA. 
Appl Environ Microbiol (2002) 68(1):114–23. doi:10.1128/AEM.68.1.114- 
123.2002 
19. Randazzo CL, Vaughan EE, Caggia C. Artisanal and experimental pecorino 
siciliano cheese: microbial dynamics during manufacture assessed by 
culturing and PCR-DGGE analyses. Int J Food Microbiol (2006) 9(1–2):1–8. 
doi:10.1016/j.ijfoodmicro.2005.11.002 
20. Hanahan D. Studies on transformation of Escherichia coli with plasmids. 
J Mol Biol (1983) 166(4):557–80. doi:10.1016/S0022-2836(83)80284-8 
21. Miljkovic D, Stosic-Grujicic S, Markovic M, Momcilovic M, Ramic Z, 
Maksimovic-Ivanic D, et al. Strain difference in susceptibility to experimental 
autoimmune encephalomyelitis between Albino Oxford and dark agouti rats 
correlates with disparity in production of IL-17, but not nitric oxide. J Neurosci 
Res (2006) 84(2):379–88. doi:10.1002/jnr.20883 
22. Francino MP. Early development of the gut microbiota and immune health. 
Pathogens (2014) 3(3):769–90. doi:10.3390/pathogens3030769 
23. Yamamura T, Da-Lin Y, Satoh J, Tabira T. Suppression of experimental allergic 
encephalomyelitis by 15-deoxyspergualin. J Neurol Sci (1987) 82(1–3):101–10. 
doi:10.1016/0022-510X(87)90010-4 
24. Matsushima S, Yoshitoshi T, Shichi H. Immunosuppression by gramicidin S of 
experimental autoimmune uveoretinitis, pinealitis and autoimmune encepha-
lomyelitis. J Ocul Pharmacol (1990) 6(3):219–26. doi:10.1089/jop.1990.6.219 
25. Popovic N, Schubart A, Goetz BD, Zhang SC, Linington C, Duncan ID. 
Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol 
(2002) 51(2):215–23. doi:10.1002/ana.10092 
26. Melzer N, Meuth SG, Torres-Salazar D, Bittner S, Zozulya AL, Weidenfeller C, 
et  al. A beta-lactam antibiotic dampens excitotoxic inflammatory CNS 
damage in a mouse model of multiple sclerosis. PLoS One (2008) 3(9):e3149. 
doi:10.1371/journal.pone.0003149 
27. Wang D, Lu Z, Hu L, Zhang Y, Hu X. Macrolide antibiotics aggravate exper-
imental autoimmune encephalomyelitis and inhibit inducible nitric oxide 
synthase. Immunol Invest (2009) 38(7):602–12. doi:10.1080/08820130903 
062194 
28. Ma K, Chen X, Chen JC, Wang Y, Zhang XM, Huang F, et  al. Rifampicin 
attenuates experimental autoimmune encephalomyelitis by inhibiting patho-
genic Th17 cells responses. J Neurochem (2016) 139(6):1151–62. doi:10.1111/
jnc.13871 
29. Ochoa-Repáraz J, Mielcarz DW, Ditrio LE, Burroughs AR, Foureau DM, 
Haque-Begum S, et  al. Role of gut commensal microflora in the develop-
ment of experimental autoimmune encephalomyelitis. J Immunol (2009) 
183(10):6041–50. doi:10.4049/jimmunol.0900747 
30. Ochoa-Repáraz J, Mielcarz DW, Haque-Begum S, Kasper LH. Induction of 
a regulatory B cell population in experimental allergic encephalomyelitis by 
alteration of the gut commensal microflora. Gut Microbes (2010) 1(2):103–8. 
doi:10.4161/gmic.1.2.11515 
31. Torow N, Hornef MW. The neonatal window of opportunity: setting the stage 
for life-long host-microbial interaction and immune homeostasis. J Immunol 
(2017) 198(2):557–63. doi:10.4049/jimmunol.1601253 
32. Zanvit P, Konkel JE, Jiao X, Kasagi S, Zhang D, Wu R, et al. Antibiotics in 
neonatal life increase murine susceptibility to experimental psoriasis. 
Nat Commun (2015) 6:8424. doi:10.1038/ncomms9424 
33. Ferrer M, Méndez-García C, Rojo D, Barbas C, Moya A. Antibiotic use and 
microbiome function. Biochem Pharmacol (2017) 134:114–26. doi:10.1016/j.
bcp.2016.09.007 
34. Hu Y, Jin P, Peng J, Zhang X, Wong FS, Wen L. Different immunological 
responses to early-life antibiotic exposure affecting autoimmune diabetes 
development in NOD mice. J Autoimmun (2016) 72:47–56. doi:10.1016/j.
jaut.2016.05.001 
35. Mu Q, Tavella VJ, Kirby JL, Cecere TE, Chung M, Lee J, et al. Antibiotics ame-
liorate lupus-like symptoms in mice. Sci Rep (2017) 7(1):13675. doi:10.1038/
s41598-017-14223-0 
36. Tamanai-Shacoori Z, Smida I, Bousarghin L, Loreal O, Meuric V, Fong SB, 
et al. Roseburia spp.: a marker of health? Future Microbiol (2017) 2:157–70. 
doi:10.2217/fmb-2016-0130 
37. St Charles JL, Bell JA, Gadsden BJ, Malik A, Cooke H, Van de Grift LK, et al. 
Guillain Barré syndrome is induced in non-obese diabetic (NOD) mice 
following Campylobacter jejuni infection and is exacerbated by antibiotics. 
J Autoimmun (2017) 77:11–38. doi:10.1016/j.jaut.2016.09.003 
38. Sun J, Furio L, Mecheri R, van der Does AM, Lundeberg E, Saveanu L, et al. 
Pancreatic β-cells limit autoimmune diabetes via an immunoregulatory 
antimicrobial peptide expressed under the influence of the gut microbiota. 
Immunity (2015) 43(2):304–17. doi:10.1016/j.immuni.2015.07.013 
39. Fahey JR, Lyons BL, Olekszak HL, Mourino AJ, Ratiu JJ, Racine JJ, et  al. 
Antibiotic-associated manipulation of the gut microbiota and phenotypic 
restoration in NOD mice. Comp Med (2017) 67(4):335–43. 
40. Vangay P, Ward T, Gerber JS, Knights D. Antibiotics, pediatric dysbiosis, 
and disease. Cell Host Microbe (2015) 17(5):553–64. doi:10.1016/j.
chom.2015.04.006 
41. Ochoa Repáraz J, Mielcarz DW, Wang Y, Begum-Haque S, Dasgupta S, 
Kasper DL, et al. A polysaccharide from the human commensal Bacteroides 
fragilis protects against CNS demyelinating disease. Mucosal Immunol (2010) 
3(5):487–95. doi:10.1038/mi.2010.29 
42. Ochoa-Repáraz J, Mielcarz DW, Ditrio LE, Burroughs AR, Begum-Haque S, 
Dasgupta S, et al. Central nervous system demyelinating disease protection 
by the human commensal Bacteroides fragilis depends on polysaccharide 
A expression. J Immunol (2010) 185(7):4101–8. doi:10.4049/jimmunol. 
1001443 
43. Wang Y, Begum-Haque S, Telesford KM, Ochoa-Repáraz J, Christy M, Kasper EJ, 
et al. A commensal bacterial product elicits and modulates migratory capacity 
of CD39(+) CD4 T regulatory subsets in the suppression of neuroinflamma-
tion. Gut Microbes (2014) 5(4):552–61. doi:10.4161/gmic.29797 
44. Wang Y, Telesford KM, Ochoa-Repáraz J, Haque-Begum S, Christy M, Kasper EJ, 
et al. An intestinal commensal symbiosis factor controls neuroinflammation 
14
Stanisavljevic´ et al. Gut Microbiota in EAE Resistance
Frontiers in Immunology | www.frontiersin.org May 2018 | Volume 9 | Article 942
via TLR2-mediated CD39 signalling. Nat Commun (2014) 5:4432. doi:10.1038/
ncomms5432 
45. Evrensel A, Ceylan ME. Fecal microbiota transplantation and its usage in neu-
ropsychiatric disorders. Clin Psychopharmacol Neurosci (2016) 14(3):231–7. 
doi:10.9758/cpn.2016.14.3.231 
46. Chitrala KN, Guan H, Singh NP, Busbee B, Gandy A, Mehrpouya-Bahrami P, 
et  al. CD44 deletion leading to attenuation of experimental autoimmune 
encephalomyelitis results from alterations in gut microbiome in mice. Eur 
J Immunol (2017) 47(7):1188–99. doi:10.1002/eji.201646792 
47. Domingues HS, Mues M, Lassmann H, Wekerle H, Krishnamoorthy G. 
Functional and pathogenic differences of Th1 and Th17 cells in experimental 
autoimmune encephalomyelitis. PLoS One (2010) 5(11):e15531. doi:10.1371/
journal.pone.0015531 
48. Pierson E, Simmons SB, Castelli L, Goverman JM. Mechanisms regulating 
regional localization of inflammation during CNS autoimmunity. Immunol 
Rev (2012) 248(1):205–15. doi:10.1111/j.1600-065X.2012.01126.x 
49. Johnson MC, Pierson ER, Spieker AJ, Nielsen AS, Posso S, Kita M, et  al. 
Distinct T  cell signatures define subsets of patients with multiple sclerosis. 
Neurol Neuroimmunol Neuroinflamm (2016) 3(5):e278. doi:10.1212/NXI. 
0000000000000278 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2018 Stanisavljević, Dinić, Jevtić, Ðedović, Momčilović, Ðokić, Golić, 
Mostarica Stojković and Miljković. This is an open-access article distributed under the 
terms of the Creative Commons Attribution License (CC BY). The use, distribution 
or reproduction in other forums is permitted, provided the original author(s) and the 
copyright owner are credited and that the original publication in this journal is cited, 
in accordance with accepted academic practice. No use, distribution or reproduction 
is permitted which does not comply with these terms.
